BEO Therapeutics

Dedicated to pre-empt gouty arthritis and to treat metabolic diseases by rebalancing the gut microbiome urate metabolism



Our unfair advantage



… combining pharmaceutical and nutritional knowledge to the ‘sweet-spot´ between food and pharma…

Beo Therapeutics works selectively with a small fraction of human gut bacteria that are considered safe for human consumption. The bacteria carry the designation Qualified Presumption of Safety (QPS).

Focusing on QPS bacteria has several benefits:

  • QPS approved bacteria can be fast-tracked into human clinical studies under food-supplement regulation (non-IND study). This approach reduces cost and timelines to clinical PoC.
  • QPS products can be commercialised as food-supplements, medical foods or as (non-) prescription drugs. The multiple options reduce product development risk.